Novel RNA Interference (RNAi)-Based Nanomedicines for Treating Viral Infections - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 235

85. Martin, A., Bodola, F., Sangar, D. V., Goettge, K., Popov, V., Rijnbrand, R.,
Lanford, R. E. and Lemon, S. M. (2003). Chronic hepatitis associated
with GB virus B persistence in a tamarin after intrahepatic inoculation
of synthetic viral RNA. Proc Natl Acad Sci U S A, 100, pp. 9962-9967.
86. McCaff rey, A. P., Nakai, H., Pandey, K., Huang, Z., Salazar, F. H., Xu, H.,
Wieland, S. F., Marion, P. L. and Kay, M. A. (2003). Inhibition of hepatitis
B virus in mice by RNA interference. Nat Biotechnol, 21, pp. 639-644.
87. McHutchison, J. G., Patel, K., Pockros, P., Nyberg, L., Pianko, S., Yu, R. Z.,
Dorr, F. A. and Kwoh, T. J. (2006). A phase I trial of an antisense inhibitor
of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C
patients. J Hepatol, 44, pp. 88-96.
88. Meister, G. and Tuschl, T. (2004). Mechanisms of gene silencing by
double-stranded RNA. Nature, 431, pp. 343-349.
89. Michienzi, A., Li, S., Zaia, J. A. and Rossi, J. J. (2002). A nucleolar TAR
decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A, 99, pp.
14047-14052.
90. Mizuta, T., Fujiwara, M., Hatta, T., Abe, T., Miyano-Kurosaki, N., Shigeta,
S., Yokota, T. and Takaku, H. (1999). Antisense oligonucleotides
directed against the viral RNA polymerase gene enhance survival of
mice infected with influenza A. Nat Biotechnol, 17, pp. 583-587.
91. Morrissey, D. V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J. A.,
Dickinson, B., McSwiggen, J. A., Vargeese, C., Bowman, K., Shaff er,
C. S., Polisky, B. A. and Zinnen, S. (2005). Activity of stabilized short
interfering RNA in a mouse model of hepatitis B virus replication.
Hepatology, 41, pp. 1349-1356.
92. Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K.,
Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., Vaish, N.,
Zinnen, S., Vargeese, C., Bowman, K., Shaff er, C. S., Jeff s, L. B., Judge, A.,
MacLachlan, I. and Polisky, B. (2005). Potent and persistent in vivo
anti-HBV activity of chemically modified siRNAs. Nat Biotechnol, 23,
pp. 1002-1007.
93. Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton,
R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., Chandran, A.,
Theodoratou, E., Sutanto, A., Sedyaningsih, E. R., Ngama, M., Munywoki,
P. K., Kartasasmita, C., Simões, E. A., Rudan, I., Weber, M. W. and Campbell,
H. (2010). Global burden of acute lower respiratory infections due to
respiratory syncytial virus in young children: a systematic review and
meta-analysis. Lancet, 375, pp. 1545-1555.
94. Negro, F. (2010). Adverse eff ects of drugs in the treatment of viral
hepatitis. Best Pract Res Clin Gastroenterol, 24, pp. 183-192.